470971328	470971328	CD	B-NP	O
|	|	NNP	I-NP	O
AECH	AECH	NNP	I-NP	O
|	|	VBD	B-VP	O
09071283	09071283	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
6159055	6159055	CD	B-NP	O
|	|	CC	I-NP	O
5/26/2006	5/26/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
PNUEMONIA	PNUEMONIA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/22/2006	4/22/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/27/2006	7/27/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
CARINE	CARINE	NN	B-NP	O
,	,	,	O	O
WALTER	WALTER	NNP	B-NP	O
MD	MD	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
Medicine	Medicine	NNP	B-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
INFORMATION	INFORMATION	NN	I-NP	O
AND	AND	CC	I-NP	O
CHIEF	CHIEF	NN	I-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Hypoxemic	Hypoxemic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
57-year-old	57-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
OSA	OSA	NN	B-NP	B-protein
,	,	,	O	O
asthma	asthma	NN	B-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
CABG	CABG	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
8/19/06	8/19/06	CD	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
total	total	JJ	I-NP	O
knee	knee	NN	I-NP	O
replacement	replacement	NN	I-NP	O
at	at	IN	B-PP	O
Dola	Dola	NNP	B-NP	O
Elan	Elan	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
8/9/06	8/9/06	CD	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

There	There	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
experienced	experience	VBD	B-VP	O
fever	fever	NN	B-NP	O
,	,	,	I-NP	O
cough	cough	NN	I-NP	O
and	and	CC	I-NP	O
dyspnea	dyspnea	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	O	O
ceftazidime	ceftazidime	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Flagyl	Flagyl	NN	B-NP	O
for	for	IN	B-PP	O
presumed	presume	VBN	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
L	L	NN	I-NP	O
ED	ED	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
temperature	temperature	NN	I-NP	O
of	of	IN	B-PP	O
97.6	97.6	CD	B-NP	O
,	,	,	O	O
pulse	pulse	NN	B-NP	O
of	of	IN	B-PP	O
88	88	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
117/70	117/70	CD	I-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
6	6	CD	B-NP	O
liters	liter	NNS	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
crackles	crackle	NNS	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
base	base	NN	I-NP	O
and	and	CC	I-NP	O
1	1	CD	I-NP	O
+	+	SYM	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
LABS	LABS	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
20	20	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
3of	3of	NN	I-NP	I-protein
5	5	CD	I-NP	I-protein
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
442	442	CD	B-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
of	of	IN	B-PP	O
0.6	0.6	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
INR	INR	NN	B-NP	B-protein
of	of	IN	B-PP	O
1.2	1.2	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
EKG	EKG	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
sinus	sinus	NN	B-NP	O
tachycardia	tachycardia	NN	I-NP	O
of	of	IN	B-PP	O
119	119	CD	B-NP	O
beats	beat	NNS	I-NP	O
per	per	IN	B-PP	O
minute	minute	NN	B-NP	O
,	,	,	O	O
normal	normal	JJ	B-NP	O
axis	axis	NN	I-NP	O
,	,	,	O	O
QRS	QRS	NN	B-NP	B-protein
104	104	CD	B-NP	I-protein
milliseconds	millisecond	NNS	I-NP	I-protein
,	,	,	O	O
QTC	QTC	NN	B-NP	B-protein
461	461	CD	I-NP	I-protein
milliseconds	millisecond	NNS	I-NP	I-protein
,	,	,	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
enlargement	enlargement	NN	I-NP	O
or	or	CC	O	O
ventricular	ventricular	JJ	B-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
,	,	,	O	O
poor	poor	JJ	B-NP	O
R-wave	R-wave	NN	I-NP	O
progression	progression	NN	I-NP	O
,	,	,	O	O
2	2	CD	B-NP	O
mm	mm	NN	I-NP	O
ST	ST	NN	I-NP	O
depressions	depression	NNS	I-NP	O
and	and	CC	O	O
T-wave	T-wave	JJ	B-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
leads	lead	NNS	B-NP	O
1	1	CD	I-NP	O
,	,	,	O	O
aVL	aVL	NN	B-NP	O
,	,	,	O	O
V5	V5	NN	B-NP	B-protein
,	,	,	O	O
V6	V6	NN	B-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
mm	mm	NN	I-NP	O
J-point	J-point	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
in	in	IN	B-PP	O
V3	V3	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	B-NP	I-protein
prior	prior	JJ	I-NP	O
EKG	EKG	NN	I-NP	O
showed	show	VBD	B-VP	O
T-wave	T-wave	JJ	B-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
1	1	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
aVL	aVL	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
ST	ST	NN	I-NP	B-protein
depressions	depression	NNS	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

Her	Her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
diffuse	diffuse	JJ	I-NP	O
patchy	patchy	NN	I-NP	O
opacities	opacity	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
presumed	presume	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
pneumonia	pneumonia	NN	B-NP	O
versus	versus	IN	B-PP	O
CHF	CHF	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	O	O
cefotaxime	cefotaxime	NN	B-NP	O
,	,	,	O	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
azithromycin	azithromycin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Medicine	Medicine	NNP	I-NP	O
Service	Service	NNP	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Left	Leave	VBN	B-NP	O
carotid	carotid	JJ	I-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
CEA	CEA	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Right	Right	RB	B-NP	O
carotid	carotid	NN	I-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
angioplasty	angioplasty	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

OSA	OSA	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Asthma	Asthma	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

CAD	CAD	NN	B-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
three-vessel	three-vessel	JJ	I-NP	O
CABG	CABG	NN	I-NP	O
in	in	IN	B-PP	O
2004	2004	CD	B-NP	O
and	and	CC	O	O
subsequent	subsequent	JJ	B-NP	O
PCI	PCI	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
ramus	ramus	NN	I-NP	O
in	in	IN	B-PP	O
2005	2005	CD	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

70-80	70-80	CD	B-NP	O
%	%	NN	I-NP	O
RCA	RCA	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
not	not	RB	B-VP	O
bypassed	bypass	VBN	I-VP	O
during	during	IN	B-PP	O
CABG	CABG	NN	B-NP	B-protein
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
ejection	ejection	NN	B-NP	O
fraction	fraction	NN	I-NP	O
45-50	45-50	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

AS	AS	JJ	B-NP	O
status	status	NN	I-NP	O
post	post	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
valve	valve	NN	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Pericarditis	Pericarditis	NN	B-NP	O
removal	removal	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Diabetes	Diabete	NNS	B-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Peripheral	Peripheral	JJ	B-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
AT	AT	NN	I-NP	O
REHAB	REHAB	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Vancomycin	Vancomycin	NN	B-NP	O
1	1	CD	I-NP	O
gram	gram	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
-LRB-	-LRB-	HYPH	B-NP	O
first	first	JJ	I-NP	O
dose	dose	NN	I-NP	O
27	27	CD	I-NP	O
of	of	IN	B-PP	O
March	March	NNP	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Ceftazidime	Ceftazidime	NN	B-NP	O
1	1	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
-LRB-	-LRB-	HYPH	B-NP	B-protein
first	first	JJ	I-NP	I-protein
dose	dose	NN	I-NP	I-protein
7/17/06	7/17/06	CD	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Flagyl	Flagyl	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
-LRB-	-LRB-	HYPH	B-NP	O
first	first	JJ	I-NP	O
dose	dose	NN	I-NP	O
7/17/06	7/17/06	CD	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Advair	Advair	NN	B-NP	O
100/50	100/50	CD	I-NP	O
inhaled	inhale	VBD	B-VP	O
b.i.d.	b.i.d.	RB	B-NP	O
5	5	CD	I-NP	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Zetia	Zetia	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Lopressor	Lopressor	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
1	1	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
1	1	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

CaCO3	CaCO3	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Cholecalciferol	Cholecalciferol	NN	B-NP	B-protein
400	400	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
p.o.	p.o.	FW	B-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Ferrous	Ferrous	JJ	B-NP	O
sulfate	sulfate	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
15	15	CD	I-NP	O
.	.	.	O	O

Folic	Folic	JJ	B-NP	O
acid	acid	NN	I-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Avapro	Avapro	RB	B-NP	O
225	225	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
100	100	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Lispro	Lispro	NN	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

P.r.n.	P.r.n.	NNP	B-NP	O
oxycodone	oxycodone	NN	I-NP	O
,	,	,	O	O
Tylenol	Tylenol	NN	B-NP	O
,	,	,	O	O
Benadryl	Benadryl	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Metamucil	Metamucil	NNP	B-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Lisinopril	Lisinopril	NNP	B-NP	O
leads	lead	VBZ	B-VP	O
to	to	TO	B-PP	O
cough	cough	NN	B-NP	O
and	and	CC	I-NP	O
metformin	metformin	NN	I-NP	O
leads	lead	VBZ	B-VP	O
to	to	TO	B-PP	O
GI	GI	NN	B-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
formerly	formerly	RB	I-VP	O
employed	employ	VBN	I-VP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
cashier	cashier	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
two	two	CD	B-NP	O
children	child	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
former	former	JJ	I-NP	O
cigarette	cigarette	NN	I-NP	O
smoker	smoker	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
does	do	VBZ	B-VP	O
not	not	RB	I-VP	O
use	use	VB	I-VP	O
alcohol	alcohol	NN	B-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
positive	positive	JJ	I-NP	O
family	family	NN	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
and	and	CC	I-NP	O
diabetes	diabetes	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
SYSTEM	SYSTEM	NN	I-NP	O
/	/	SYM	B-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
:	:	:	O	O
Persistent	Persistent	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
1	1	CD	I-NP	O
.	.	.	O	O

Hypoxemic	Hypoxemic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
1/7/06	1/7/06	CD	B-NP	O
,	,	,	O	O
shortly	shortly	RB	B-ADVP	O
after	after	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
medical	medical	JJ	I-NP	O
floor	floor	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
respiratory	respiratory	JJ	B-NP	O
distress	distress	NN	I-NP	O
with	with	IN	B-PP	O
tachypnea	tachypnea	NN	B-NP	O
,	,	,	O	O
accessory	accessory	JJ	B-NP	O
muscle	muscle	NN	I-NP	O
use	use	NN	I-NP	O
and	and	CC	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
68	68	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
6	6	CD	B-NP	O
liters	liter	NNS	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
nonrebreather	nonrebreather	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
increased	increase	VBD	B-VP	O
to	to	TO	B-PP	O
93	93	CD	B-NP	O
%	%	NN	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
respiratory	respiratory	JJ	B-NP	O
distress	distress	NN	I-NP	O
with	with	IN	B-PP	O
tachypnea	tachypnea	NN	B-NP	O
and	and	CC	O	O
accessory	accessory	JJ	B-NP	O
muscle	muscle	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
and	and	CC	O	O
transferred	transfer	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Medical	Medical	NNP	I-NP	O
Intensive	Intensive	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
component	component	NN	I-NP	O
of	of	IN	B-PP	O
superimposed	superimpose	VBN	B-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	I-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
with	with	IN	B-PP	O
IV	IV	CD	B-NP	O
Lasix	Lasix	NNP	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
code	code	NN	I-NP	O
green	green	NN	I-NP	O
on	on	IN	B-PP	O
7/30/06	7/30/06	CD	B-NP	O
during	during	IN	B-PP	O
an	an	DT	B-NP	O
ETT	ETT	NN	I-NP	O
tube	tube	NN	I-NP	O
change	change	NN	I-NP	O
,	,	,	O	O
wherein	wherein	IN	B-PP	O
a	a	DT	B-NP	O
patent	patent	NN	I-NP	O
airway	airway	NN	I-NP	O
was	be	VBD	B-VP	O
transiently	transiently	RB	B-NP	O
loss	loss	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
slow	slow	JJ	B-ADJP	O
to	to	TO	B-VP	O
wean	wean	VB	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
ventilator	ventilator	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chest	chest	NN	I-NP	O
imaging	imaging	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
persistent	persistent	JJ	B-NP	O
bilateral	bilateral	JJ	I-NP	O
opacifications	opacification	NNS	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
after	after	IN	B-PP	O
an	an	DT	B-NP	O
initial	initial	JJ	I-NP	O
infectious	infectious	JJ	I-NP	O
insult	insult	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
ARDS	ARDS	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
9/14/06	9/14/06	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
bronchoscopy	bronchoscopy	NN	B-NP	O
and	and	CC	I-NP	O
BAL	BAL	NN	I-NP	O
revealing	reveal	VBG	B-VP	O
MRSA	MRSA	NN	B-NP	O
and	and	CC	I-NP	O
HSV	HSV	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
acyclovir	acyclovir	NN	B-NP	O
for	for	IN	B-PP	O
presumed	presume	VBN	B-NP	O
HSV	HSV	NN	I-NP	O
tracheobronchitis	tracheobronchitis	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
her	her	PRP$	B-NP	O
inability	inability	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
weaned	wean	VBN	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
vent	vent	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
tracheostomy	tracheostomy	NN	I-NP	O
on	on	IN	B-PP	O
4/17/06	4/17/06	CD	B-NP	O
.	.	.	O	O

Post-tracheostomy	Post-tracheostomy	JJ	B-ADJP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
alternated	alternate	VBN	B-VP	O
between	between	IN	B-PP	O
pressure	pressure	NN	B-NP	O
support	support	NN	I-NP	O
ventilation	ventilation	NN	I-NP	O
with	with	IN	B-PP	O
low	low	JJ	B-NP	O
driving	driving	NN	I-NP	O
pressure	pressure	NN	I-NP	O
and	and	CC	I-NP	O
PEEP	PEEP	NN	I-NP	B-protein
with	with	IN	B-PP	O
a	a	DT	B-NP	O
trach	trach	NN	I-NP	O
collar	collar	NN	I-NP	O
.	.	.	O	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Fevers	Fever	NNS	B-NP	O
.	.	.	O	O

From	From	IN	B-PP	O
1/7/06	1/7/06	CD	B-NP	O
to	to	TO	B-PP	O
7/28/06	7/28/06	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	I-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
for	for	IN	B-PP	O
hospital	hospital	NN	B-NP	O
acquired	acquire	VBD	B-VP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
discontinuation	discontinuation	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
spike	spike	VB	I-VP	O
fevers	fever	NNS	B-NP	O
and	and	CC	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
leukocytosis	leukocytosis	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
verification	verification	NN	B-NP	O
into	into	IN	B-PP	O
source	source	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	B-cell_line
fevers	fever	NNS	I-NP	I-cell_line
included	include	VBD	B-VP	I-cell_line
serial	serial	JJ	B-NP	I-cell_line
blood	blood	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
,	,	,	O	O
urine	urine	NN	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
and	and	CC	O	O
C-dif	C-dif	NN	B-NP	B-protein
.	.	.	O	O

Positive	Positive	JJ	B-NP	O
data	datum	NNS	I-NP	O
included	include	VBD	B-VP	O
:	:	:	O	O
7/28/06	7/28/06	CD	B-NP	O
,	,	,	O	O
urine	urine	NN	B-NP	O
culture	culture	NN	I-NP	O
with	with	IN	B-PP	O
yeast	yeast	NN	B-NP	O
,	,	,	O	O
7/28/06	7/28/06	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
culture	culture	NN	I-NP	O
with	with	IN	B-PP	O
coag-negative	coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
9/14/06	9/14/06	CD	B-NP	O
BAL	BAL	NN	I-NP	O
washings	washing	NNS	I-NP	O
with	with	IN	B-PP	O
HSV	HSV	NN	B-NP	O
,	,	,	O	O
9/14/06	9/14/06	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
culture	culture	NN	I-NP	O
with	with	IN	B-PP	O
coag-negative	coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
7/11/06	7/11/06	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
culture	culture	NN	I-NP	O
with	with	IN	B-PP	O
coag-negative	coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
2/29/06	2/29/06	CD	B-NP	O
,	,	,	O	O
urine	urine	NN	B-NP	O
culture	culture	NN	I-NP	O
with	with	IN	B-PP	O
yeast	yeast	NN	B-NP	O
,	,	,	O	O
2/29/06	2/29/06	CD	B-NP	O
BAL	BAL	NN	I-NP	O
washings	washing	NNS	I-NP	O
with	with	IN	B-PP	O
MRSA	MRSA	NN	B-NP	B-protein
,	,	,	O	O
10/28/06	10/28/06	CD	B-NP	O
urine	urine	NN	I-NP	O
with	with	IN	B-PP	O
yeast	yeast	NN	B-NP	O
urine	urine	NN	I-NP	O
with	with	IN	B-PP	O
yeast	yeast	NN	B-NP	O
,	,	,	O	O
10/28/06	10/28/06	CD	B-NP	O
,	,	,	I-NP	O
6/23/06	6/23/06	CD	I-NP	O
,	,	,	I-NP	O
4/17/06	4/17/06	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
10/11/06	10/11/06	CD	B-NP	O
sputum	sputum	NN	I-NP	O
with	with	IN	B-PP	O
MRSA	MRSA	NN	B-NP	B-protein
.	.	.	O	O

7/28/06	7/28/06	CD	B-NP	O
,	,	,	O	O
chest	chest	NN	B-NP	O
CT	CT	NN	I-NP	O
with	with	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
opacification	opacification	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lung	lung	NN	I-NP	O
parenchyma	parenchyma	NN	I-NP	O
.	.	.	O	O

2/29/06	2/29/06	CD	B-NP	O
facial	facial	JJ	I-NP	O
CT	CT	NN	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
sphenoid	sphenoid	JJ	I-NP	O
maxillary	maxillary	JJ	I-NP	O
thickening	thickening	NN	I-NP	O
.	.	.	O	O

2/29/06	2/29/06	CD	B-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
with	with	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
opacification	opacification	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lung	lung	NN	I-NP	O
parenchyma	parenchyma	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
2/29/06	2/29/06	CD	I-NP	O
abdominal	abdominal	JJ	I-NP	O
CT	CT	NN	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
infection	infection	NN	I-NP	O
,	,	,	O	O
2/29/06	2/29/06	CD	B-NP	O
TTE	TTE	NN	I-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
obvious	obvious	JJ	I-NP	O
vegetations	vegetation	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
10/11/06	10/11/06	CD	B-NP	O
tap	tap	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
knee	knee	NN	I-NP	O
grew	grow	VBD	B-VP	O
no	no	DT	B-NP	O
organisms	organism	NNS	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
light	light	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
data	datum	NNS	I-NP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
indwelling	indwell	VBG	I-NP	O
catheters	catheter	NNS	I-NP	O
were	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
treatment	treatment	NN	B-NP	O
with	with	IN	B-PP	O
linezolid	linezolid	NN	B-NP	O
x7	x7	CD	B-NP	O
days	day	NNS	I-NP	O
for	for	IN	B-PP	O
MRSA	MRSA	NN	B-NP	O
line	line	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
underwent	undergo	VBD	B-VP	O
treatment	treatment	NN	B-NP	O
with	with	IN	B-PP	O
acyclovir	acyclovir	NN	B-NP	O
x10	x10	CD	B-NP	O
days	day	NNS	I-NP	O
for	for	IN	B-PP	O
HSV	HSV	NN	B-NP	O
tracheobronchitis	tracheobronchitis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
aforementioned	aforementioned	JJ	I-NP	O
antibiosis	antibiosis	NN	I-NP	O
was	be	VBD	B-VP	O
mostly	mostly	RB	B-ADJP	O
prophylactic	prophylactic	JJ	I-ADJP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
intermittent	intermittent	JJ	I-NP	O
fevers	fever	NNS	I-NP	O
were	be	VBD	B-VP	O
not	not	RB	O	O
infectious	infectious	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
rather	rather	RB	B-VP	O
reflected	reflect	VBD	I-VP	O
a	a	DT	B-NP	O
drug	drug	NN	I-NP	O
allergy	allergy	NN	I-NP	O
,	,	,	O	O
most	most	RBS	B-ADJP	O
likely	likely	JJ	I-ADJP	O
to	to	TO	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
hypothesis	hypothesis	NN	I-NP	O
was	be	VBD	B-VP	O
supported	support	VBN	I-VP	O
by	by	IN	B-PP	O
a	a	DT	B-NP	O
robust	robust	JJ	I-NP	O
eosinophilia	eosinophilia	NN	I-NP	O
coinciding	coincide	VBG	B-VP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
administration	administration	NN	I-NP	O
.	.	.	O	O

Shortly	Shortly	RB	B-ADVP	O
after	after	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
discontinuation	discontinuation	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
fevers	fever	NNS	I-NP	O
resolved	resolve	VBD	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
for	for	IN	B-PP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
48	48	CD	I-NP	O
hours	hour	NNS	I-NP	O
off	off	IN	B-PP	O
all	all	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
transfer	transfer	VB	I-VP	O
to	to	TO	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	NNP	B-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Volume	Volume	NN	B-NP	O
status	status	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
admission	admission	NN	I-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
106.2	106.2	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
unclear	unclear	JJ	B-ADJP	O
what	what	WP	B-NP	O
her	her	PRP$	B-NP	O
dry	dry	JJ	I-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
that	that	IN	B-SBAR	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
contributing	contribute	VBG	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
slow	slow	JJ	I-NP	O
ventilator	ventilator	NN	I-NP	O
wean	wean	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
combination	combination	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
and	and	CC	I-NP	O
Diuril	Diuril	NNP	I-NP	O
followed	follow	VBN	B-VP	O
by	by	IN	B-PP	O
combinations	combination	NNS	B-NP	O
of	of	IN	B-PP	O
torsemide	torsemide	NN	B-NP	O
and	and	CC	O	O
Diuril	Diuril	NNP	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
100.7	100.7	CD	B-NP	O
kilograms	kilogram	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
diuretic	diuretic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
with	with	IN	B-PP	O
torsemide	torsemide	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
and	and	CC	O	O
Diuril	Diuril	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
diuretic	diuretic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	O
intake	intake	NN	I-NP	O
is	be	VBZ	B-VP	O
adjusted	adjust	VBN	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
very	very	RB	B-ADVP	O
closely	closely	RB	I-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Pump	Pump	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
echocardiogram	echocardiogram	NN	B-NP	O
on	on	IN	B-PP	O
11/19/06	11/19/06	CD	B-NP	O
,	,	,	I-NP	O
7/17/06	7/17/06	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
2/29/06	2/29/06	CD	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
the	the	DT	B-NP	O
whole	whole	NN	I-NP	O
,	,	,	O	O
these	these	DT	B-NP	O
studies	study	NNS	I-NP	O
revealed	reveal	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
45-50	45-50	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
concentric	concentric	JJ	B-NP	O
LVH	LVH	NN	I-NP	O
,	,	,	O	O
global	global	JJ	B-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
with	with	IN	B-PP	O
regional	regional	JJ	B-NP	O
variation	variation	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
left	left	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
enlargement	enlargement	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
tricuspid	tricuspid	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
mild	mild	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
pulmonary	pulmonary	JJ	B-NP	O
artery	artery	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
40s	40	NNS	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
her	her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Lopressor	Lopressor	NN	B-NP	O
and	and	CC	I-NP	O
diuretics	diuretic	NNS	I-NP	O
as	as	RB	B-ADVP	O
above	above	RB	I-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
allergy	allergy	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
cough	cough	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
low-dose	low-dose	JJ	B-NP	B-protein
ARB	ARB	NN	I-NP	I-protein
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Ischemia	Ischemia	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
three-vessel	three-vessel	JJ	I-NP	O
CABG	CABG	NN	I-NP	O
and	and	CC	O	O
subsequent	subsequent	JJ	B-NP	O
single-vessel	single-vessel	JJ	I-NP	O
PPI	PPI	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
RCA	RCA	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
70-80	70-80	CD	B-NP	O
%	%	NN	I-NP	O
that	that	WDT	B-NP	O
has	have	VBZ	B-VP	O
not	not	RB	I-VP	O
intervened	intervene	VBN	I-VP	O
upon	upon	IN	B-PP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
respiratory	respiratory	JJ	B-NP	O
distress	distress	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
sinus	sinus	NN	B-NP	O
tachycardia	tachycardia	NN	I-NP	O
with	with	IN	B-PP	O
rate	rate	NN	B-NP	O
related	relate	VBN	B-VP	O
to	to	TO	B-PP	O
lateral	lateral	JJ	B-NP	O
ST	ST	NN	I-NP	O
depressions	depression	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
biomarkers	biomarker	NNS	I-NP	O
were	be	VBD	B-VP	O
positive	positive	JJ	B-ADJP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
NSTEMI	NSTEMI	NN	B-NP	B-protein
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
experienced	experienced	JJ	I-NP	O
demand	demand	NN	I-NP	O
ischemia	ischemia	NN	I-NP	O
rather	rather	RB	B-CONJP	O
than	than	IN	I-CONJP	O
an	an	DT	B-NP	O
acute	acute	JJ	I-NP	O
plaque	plaque	NN	I-NP	O
rupture	rupture	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
10/8/06	10/8/06	CD	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
troponin	troponin	NN	I-NP	O
peaked	peak	VBD	B-VP	O
at	at	IN	B-PP	O
8.53	8.53	CD	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
CK	CK	NN	I-NP	B-protein
at	at	IN	B-PP	O
275	275	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
MB	MB	NN	I-NP	B-protein
of	of	IN	B-PP	O
16.3	16.3	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Zocor	Zocor	NNP	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
as	as	IN	B-PP	O
detailed	detailed	JJ	B-ADJP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
likely	likely	RB	I-VP	O
warrant	warrant	VB	I-VP	O
Cardiology	Cardiology	NN	B-NP	O
followup	followup	NN	I-NP	O
with	with	IN	B-PP	O
possible	possible	JJ	B-NP	O
RCA	RCA	NN	I-NP	O
revascularization	revascularization	NN	I-NP	O
.	.	.	O	O

Neuro	Neuro	NNP	B-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Sedation	Sedation	NN	B-NP	O
:	:	:	O	O
While	While	IN	B-SBAR	O
intubated	intubate	VBN	B-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
IV	IV	CD	B-NP	O
Versed	Verse	VBN	I-NP	O
and	and	CC	I-NP	O
fentanyl	fentanyl	NN	I-NP	O
titrated	titrate	VBN	B-VP	O
to	to	TO	B-PP	O
light	light	NN	B-NP	O
sedation	sedation	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
her	her	PRP$	B-NP	O
tracheostomy	tracheostomy	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Versed	Versed	JJ	I-NP	O
and	and	CC	I-NP	O
fentanyl	fentanyl	NN	I-NP	O
drips	drip	NNS	I-NP	O
were	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Seroquel	Seroquel	NN	B-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
to	to	TO	B-VP	O
preclude	preclude	VB	I-VP	O
nighttime	nighttime	NN	B-NP	O
agitation	agitation	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
QTC	QTC	NN	I-NP	B-protein
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
while	while	IN	B-SBAR	O
on	on	IN	B-PP	O
Seroquel	Seroquel	NNP	B-NP	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
initially	initially	RB	B-ADVP	O
received	receive	VBD	B-VP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
via	via	IN	B-PP	O
feeding	feeding	NN	B-NP	O
tube	tube	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
PEG	PEG	NN	I-NP	O
placement	placement	NN	I-NP	O
on	on	IN	B-PP	O
4/17/06	4/17/06	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
continued	continue	VBD	B-VP	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
passed	pass	VBD	B-VP	O
speech	speech	NN	B-NP	O
and	and	CC	I-NP	O
Swallow	Swallow	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
thus	thus	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
p.o.	p.o.	FW	B-NP	O
feeds	feed	NNS	I-NP	O
with	with	IN	B-PP	O
aspiration	aspiration	NN	B-NP	O
precautions	precaution	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
received	receive	VBD	B-VP	O
supplemental	supplemental	JJ	B-NP	O
multivitamins	multivitamin	NNS	I-NP	O
,	,	,	O	O
calcium	calcium	NN	B-NP	O
carbonate	carbonate	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
cholecalciferol	cholecalciferol	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
require	require	VB	I-VP	O
speech	speech	NN	B-NP	O
and	and	CC	O	O
swallow	swallow	VB	B-VP	O
evaluation	evaluation	NN	B-NP	O
at	at	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

Now	Now	RB	B-ADVP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
awake	awake	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
tolerate	tolerate	VB	I-VP	O
oral	oral	JJ	B-NP	O
feeds	feed	NNS	I-NP	O
with	with	IN	B-PP	O
aspiration	aspiration	NN	B-NP	O
precautions	precaution	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Bowel	Bowel	NNP	B-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Colace	Colace	NN	B-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Dulcolax	Dulcolax	NN	B-NP	O
.	.	.	O	O

Heme	Heme	NNP	B-NP	B-protein
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Anemia	Anemia	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
known	know	VBN	I-VP	O
iron	iron	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
and	and	CC	I-NP	O
folate	folate	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
may	may	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
colonoscopy	colonoscopy	NN	I-NP	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
not	not	RB	I-VP	O
had	have	VBN	I-VP	O
one	one	CD	B-NP	O
recently	recently	RB	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Bleeding	Bleed	VBG	B-VP	O
from	from	IN	B-PP	O
tracheostomy	tracheostomy	NN	B-NP	O
site	site	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
4/24/06	4/24/06	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
bleeding	bleed	VBG	I-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	B-DNA
tracheostomy	tracheostomy	NN	I-NP	I-DNA
site	site	NN	I-NP	I-DNA
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
remained	remain	VBD	B-VP	O
hemodynamically	hemodynamically	RB	B-ADJP	O
stable	stable	JJ	I-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
bronchoscopy	bronchoscopy	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
active	active	JJ	I-NP	O
bleeding	bleeding	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
mild	mild	JJ	I-NP	O
bleeding	bleeding	NN	I-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
relate	relate	VB	I-VP	O
to	to	TO	B-PP	O
suction	suction	NN	B-NP	O
trauma	trauma	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
prophylactic	prophylactic	JJ	I-NP	O
heparin	heparin	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
x1	x1	NN	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
prophylactic	prophylactic	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
because	because	IN	B-SBAR	O
her	her	PRP$	B-NP	O
DVT	DVT	NN	I-NP	O
risk	risk	NN	I-NP	O
is	be	VBZ	B-VP	O
so	so	RB	B-ADJP	O
high	high	JJ	I-ADJP	O
.	.	.	O	O

Should	Should	MD	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
have	have	VBP	B-VP	O
intense	intense	JJ	B-NP	O
bleeding	bleeding	NN	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
tracheostomy	tracheostomy	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
,	,	,	O	O
a	a	DT	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
or	or	CC	O	O
hemodynamic	hemodynamic	JJ	B-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
heparin	heparin	NN	I-NP	O
subcu	subcu	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
closely	closely	RB	B-ADVP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
transfused	transfuse	VBN	I-VP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
also	also	RB	B-ADVP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
probably	probably	RB	B-ADVP	O
undergo	undergo	VBP	B-VP	O
reevaluation	reevaluation	NN	B-NP	O
by	by	IN	B-PP	O
Pulmonary	Pulmonary	JJ	B-NP	O
or	or	CC	I-NP	O
Thoracics	Thoracics	NNP	I-NP	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabete	NNS	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Lantus	Lantus	NNP	B-NP	O
plus	plus	CC	O	O
regular	regular	JJ	B-NP	O
insulin	insulin	NN	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

plus	plus	CC	O	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	B-protein
insulin	insulin	NN	I-NP	I-protein
while	while	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
insulin	insulin	NN	I-NP	B-protein
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Lantus	Lantus	NNP	B-NP	O
100	100	CD	I-NP	O
subq	subq	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
got	get	VBD	B-VP	O
her	her	PRP$	B-NP	O
first	first	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
100	100	CD	B-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
evening	evening	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
morning	morning	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
were	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
100s	100	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
closely	closely	RB	B-ADVP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
one	one	CD	I-NP	O
or	or	CC	I-NP	O
two	two	CD	I-NP	O
days	day	NNS	I-NP	O
at	at	IN	B-PP	O
rehab	rehab	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
every	every	DT	B-NP	O
2-3	2-3	NN	I-NP	O
hours	hour	NNS	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
insulin	insulin	NN	I-NP	B-protein
should	should	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
accordingly	accordingly	RB	B-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
insulin	insulin	NN	I-NP	O
dose	dose	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
if	if	IN	B-SBAR	O
her	her	PRP$	B-NP	O
tube	tube	NN	I-NP	O
feeds	feed	NNS	I-NP	O
are	be	VBP	B-VP	O
cycled	cycle	VBN	I-VP	O
rather	rather	RB	B-PP	O
than	than	IN	I-PP	O
given	give	VBN	B-VP	O
continuously	continuously	RB	B-ADVP	O
or	or	CC	O	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
NPO	NPO	NNP	B-NP	O
.	.	.	O	O

Ortho	Ortho	NNP	B-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Total	Total	JJ	B-NP	O
knee	knee	NN	I-NP	O
replacement	replacement	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	IN	B-PP	O
right	right	JJ	B-NP	O
total	total	JJ	I-NP	O
knee	knee	NN	I-NP	O
replacement	replacement	NN	I-NP	O
on	on	IN	B-PP	O
8/19/06	8/19/06	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
right	right	JJ	I-NP	O
knee	knee	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
well-healed	well-healed	JJ	I-NP	O
incision	incision	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
erythematous	erythematous	JJ	B-NP	O
or	or	CC	I-NP	O
tender	tender	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	B-ADVP	O
on	on	IN	B-PP	O
low-dose	low-dose	JJ	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
with	with	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
given	give	VBN	I-VP	O
her	her	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
illness	illness	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
need	need	NN	I-NP	O
for	for	IN	B-PP	O
procedures	procedure	NNS	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
heparin	heparin	NN	B-NP	B-protein
subq	subq	NN	I-NP	I-protein
prophylactic	prophylactic	JJ	I-NP	I-protein
doses	dose	NNS	I-NP	I-protein
5000	5000	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
t.i.d.	t.i.d.	VBN	B-VP	O
as	as	IN	B-SBAR	O
described	describe	VBN	B-VP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
rehabilitation	rehabilitation	NN	B-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
knee	knee	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
subcutaneous	subcutaneous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
and	and	CC	I-NP	O
Nexium	Nexium	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Access	Access	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
peripheral	peripheral	JJ	B-NP	O
IVs	IV	NNS	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
3/8/06	3/8/06	CD	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
.	.	.	O	O

Heart	Heart	NN	B-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
80s	80	NNS	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
100s-130s	100s-130s	CD	I-NP	O
/	/	SYM	I-NP	O
60s-80s	60s-80	NNS	I-NP	O
.	.	.	O	O

Discharge	Discharge	NN	B-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
100.7	100.7	CD	B-NP	O
kilograms	kilogram	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
drowsy	drowsy	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
arouseable	arouseable	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
breathing	breathe	VBG	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
trach	trach	NN	I-NP	B-protein
collar	collar	NN	I-NP	I-protein
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
breath	breath	NN	B-NP	O
sounds	sound	NNS	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bases	base	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	I-NP	O
S2	S2	NN	I-NP	B-protein
with	with	IN	B-PP	O
a	a	DT	B-NP	O
2/6	2/6	CD	I-NP	O
systolic	systolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
lower	low	JJR	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
nontender	nontender	JJ	I-ADJP	O
with	with	IN	B-PP	O
positive	positive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
trach	trach	NN	I-NP	O
and	and	CC	I-NP	O
PEG	PEG	NN	I-NP	B-DNA
site	site	NN	I-NP	I-DNA
were	be	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
surrounding	surround	VBG	I-NP	O
erythema	erythema	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
were	be	VBD	B-VP	O
warm	warm	JJ	B-ADJP	O
without	without	IN	B-PP	O
edema	edema	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
trach	trach	NN	B-NP	O
collar	collar	NN	I-NP	O
with	with	IN	B-PP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
FiO2	FiO2	NN	I-NP	O
and	and	CC	I-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
labs	lab	NNS	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
21	21	CD	B-NP	O
,	,	,	O	O
stable	stable	JJ	B-ADJP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
28	28	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
436	436	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chem-7	chem-7	NN	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
sodium	sodium	NN	I-NP	O
of	of	IN	B-PP	O
131	131	NN	B-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
3	3	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
87	87	CD	I-NP	O
,	,	,	O	O
CO2	CO2	NN	B-NP	O
32	32	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
67	67	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
0.8	0.8	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
glucose	glucose	NN	B-NP	B-protein
154	154	CD	I-NP	I-protein
.	.	.	O	O

Her	Her	PRP$	B-NP	O
LFTs	LFT	NNS	I-NP	B-protein
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
1.1	1.1	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-protein
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
microdata	microdata	NNS	I-NP	O
showed	show	VBD	B-VP	O
sputum	sputum	NN	B-NP	O
with	with	IN	B-PP	O
few	few	JJ	B-NP	O
polys	poly	NNS	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
few	few	JJ	I-NP	O
gram-positive	gram-positive	JJ	I-NP	O
cocci	coccus	NNS	I-NP	O
in	in	IN	B-PP	O
clusters	cluster	NNS	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
trach	trach	NN	I-NP	O
in	in	IN	B-PP	O
place	place	NN	B-NP	O
and	and	CC	O	O
bilateral	bilateral	JJ	B-NP	O
hazy	hazy	JJ	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
resolving	resolve	VBG	B-VP	O
ARDS	ARDS	NN	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
addendum	addendum	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
with	with	IN	B-PP	O
discharge	discharge	NN	B-NP	O
medications	medication	NNS	I-NP	O
and	and	CC	I-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
rehab	rehab	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
weight	weight	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
initially	initially	RB	B-ADVP	O
be	be	VB	B-VP	O
monitored	monitor	VBN	I-VP	O
every	every	DT	B-NP	O
2-3	2-3	CD	I-NP	O
hours	hour	NNS	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
that	that	DT	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
sugar	sugar	NN	I-NP	O
monitoring	monitoring	NN	I-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
spaced	space	VBN	I-VP	O
out	out	RP	B-PRT	O
to	to	TO	B-VP	O
t.i.d.	t.i.d.	VB	I-VP	O
or	or	CC	O	O
whenever	whenever	WRB	B-ADVP	O
deemed	deem	VBN	B-VP	O
appropriate	appropriate	JJ	B-ADJP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
physician	physician	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
facility	facility	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
particularly	particularly	RB	B-ADVP	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
any	any	DT	B-NP	O
bleeding	bleeding	NN	I-NP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
tracheostomy	tracheostomy	NN	I-NP	O
site	site	NN	I-NP	O
;	;	:	O	O
otherwise	otherwise	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
every	every	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
if	if	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
any	any	DT	B-NP	O
fever	fever	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
daily	daily	RB	B-ADVP	O
in	in	IN	B-PP	O
light	light	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
changing	change	VBG	I-NP	O
diuretic	diuretic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
in	in	IN	B-PP	O
's	's	POS	B-NP	O
and	and	CC	O	O
out	out	RP	B-PRT	O
's	's	POS	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
closely	closely	RB	B-ADVP	O
.	.	.	O	O

CONTACTS	CONTACTS	NNS	B-NP	O
AT	AT	IN	B-PP	O
THE	THE	DT	B-NP	O
HOSPITAL	HOSPITAL	NN	I-NP	O
:	:	:	O	O
Liri	Liri	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
Of	Of	IN	B-PP	O
regarding	regard	VBG	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
inpatient	inpatient	NN	I-NP	O
course	course	NN	I-NP	O
or	or	CC	O	O
Dr.	Dr.	NNP	B-NP	O
Julio	Julio	NNP	I-NP	O
Golding	Golding	NNP	I-NP	O
.	.	.	O	O

Contacts	Contact	NNS	B-NP	O
regarding	regard	VBG	B-PP	O
follow	follow	NN	B-NP	O
up	up	RP	B-PRT	O
issues	issue	NNS	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Adrian	Adrian	NNP	I-NP	O
Mckinley	Mckinley	NNP	I-NP	O
Rickenbaker	Rickenbaker	NNP	I-NP	O
at	at	IN	B-PP	O
Mawahutche	Mawahutche	NNP	B-NP	O
Rehabilitation	Rehabilitation	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
Of	Of	IN	B-PP	O
080-524-3286	080-524-3286	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
healthcare	healthcare	NN	I-NP	O
proxy	proxy	NN	I-NP	O
is	be	VBZ	B-VP	O
her	her	PRP$	B-NP	O
sister	sister	NN	I-NP	O
,	,	,	O	O
Kyle	Kyle	NNP	B-NP	O
Lusk	Lusk	NNP	I-NP	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
registered	register	VBN	I-NP	O
nurse	nurse	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
telephone	telephone	NN	I-NP	O
number	number	NN	I-NP	O
507-122-9398	507-122-9398	CD	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
and	and	CC	O	O
581-981-9887	581-981-9887	CD	B-NP	O
cell	cell	NN	I-NP	O
phone	phone	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
9-3627813	9-3627813	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Geraldo	Geraldo	NNP	B-NP	O
Lanny	Lanny	NNP	I-NP	O
Bogda	Bogda	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Los	Los	NNP	I-NP	O
Di	Di	NNP	I-NP	O
Wi	Wi	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Raleigh	Raleigh	NNP	B-NP	O
Semmens	Semmens	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
DELIBERTIS	DELIBERTIS	NNP	B-NP	O
,	,	,	O	O
BRADLY	BRADLY	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BEAGLEY	BEAGLEY	NNP	B-NP	O
,	,	,	O	O
ORLANDO	ORLANDO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
4434301	4434301	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
3/8/06	3/8/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
3/8/06	3/8/06	CD	B-NP	O

